Palliative care in late-stage dementia has been stuck with terrible choices for decades. When severe agitation strikes, clinicians often end up turning to heavy off-label sedatives—antipsychotics, benzodiazepines, and opioids—that dull symptoms by flattening the patient, increasing fall risks and mortality. The Phase 2 LiBBY trial changes that calculation entirely.
Presented at the Alzheimer’s Association International Conference 2026 (AAIC 2026) in London, the trial's topline data shows that a specific oral combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) cuts severe agitation fast, maintains that relief across 12 weeks, and avoids drug-related serious adverse events. For anyone responsible for risk controls and operational standards, these results offer a textbook lesson in how structured protocols turn high-risk interventions into manageable care.
Trial Design and the T2 Dosing Strategy
The LiBBY trial—short for Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol—was funded primarily by the National Institute on Aging (NIA), part of the National Institutes of Health, and conducted by the Alzheimer’s Clinical Trial Consortium (ACTC). It evaluated 120 hospice-eligible participants suffering from advanced dementia and severe, clinically significant agitation across multiple U.S. research centers, including the Pennington Biomedical Research Center.
Managing clinical trials in hospice-eligible populations is notoriously complex. Patients near the end of life are frequently excluded from clinical research due to physical frailty and communication barriers. Lead investigator Dr. Jacobo Mintzer, psychiatrist at the Ralph H. Johnson VA Healthcare System and professor at the Medical University of South Carolina, noted that this robust, randomized controlled study represents a major step forward for a population long overlooked in medical research.
The trial tested a proprietary oral oil formulation designated as T2, containing 2 mg of THC and 100 mg of CBD per dose. Researchers implemented a careful two-step titration schedule:
- Week 1 (Lead-in): Participants received a half dose twice daily, bringing total daily exposure to 2 mg THC and 100 mg CBD (1 mg THC / 50 mg CBD per administration).
- Weeks 2 through 12 (Full Intervention): Dosing scaled up to the target intervention level of one full dose twice daily, delivering 4 mg THC and 200 mg CBD daily (2 mg THC / 100 mg CBD per administration).
Control group participants received a matching placebo oil on the exact same schedule.
Quantifying Efficacy Across 12 Weeks
The primary endpoint measured changes in score on the Cohen-Mansfield Agitation Inventory (CMAI) at Week 2. The results were immediate and decisive. By the second week, patients receiving the T2 cannabinoid formulation achieved a 6.27-point greater reduction in CMAI scores compared to placebo.
That difference wasn't just statistically significant; it translated directly into rapid clinical relief. According to data reported by Neuroscience News, clinician-rated global improvement at Week 2 hit 83.9% in the treatment group, compared to just 30.5% in the placebo group.
Rather than fading over time, the therapeutic benefit compounded:
- Agitation Reduction at Week 12: The treatment arm maintained an 8.23-point greater score reduction on the CMAI over placebo.
- Global Clinical Improvement at Week 12: Clinicians observed meaningful overall improvement in 87.2% of treated patients versus 23.6% of those on placebo.
Dr. Jeff Keller, Director of the Institute for Dementia Research and Prevention at Pennington Biomedical and site principal investigator, stressed that the magnitude and speed of agitation reduction were remarkable. For patients who can no longer communicate their physical discomfort or distress through speech, reducing verbal tension, vocal outbursts, pacing, and physical hostility restores basic dignity at the end of life. Related research on building resilience against Alzheimer's disease underscores how non-pharmacological care and targeted interventions must work in tandem.
Evaluating the Trial's Safety and Adverse Events
In any high-vulnerability study population, safety controls matter just as much as primary efficacy numbers. Over the 12-week double-blind period, overall adverse event rates remained comparable between both arms: 46.7% in the treatment group versus 42.4% in the placebo group.
Serious adverse events (SAEs) occurred in 23.3% of treatment participants compared to 11.9% of placebo participants. However, formal safety reviews by trial investigators confirmed that zero serious adverse events were related to the study drug. Given that hospice-eligible dementia patients present with severe baseline comorbidities, expected underlying illness accounts for these events.
Dr. Frank Greenway, Chief Medical Officer at Pennington Biomedical, emphasized that the THC/CBD combination proved safer and produced far less sedation than traditional pharmacological options. Off-label prescribing of antipsychotics, benzodiazepines, and opioids often leads to severe motor impairment, increasing catastrophic fall risks detailed in our analysis of fall risks in dementia and neurological disorders.
Why a Security & Compliance Analyst Analyzes Clinical Risk Protocols
Whether you are auditing a cloud security incident response playbook or reviewing high-stakes medical protocols, core risk management principles remain identical. A security & compliance analyst looks for clear operational baselines, rigorous control verification, and failure domain containment.
In enterprise IT, an analyst might rely on a security & compliance analyzer veeam integration or monitor policy posture inside the security & compliance center office 365 environments 365 days a year. In clinical trial execution, researchers face the same requirement: enforcing deterministic protocols to protect vulnerable assets.
The LiBBY trial demonstrates three fundamental control principles:
- Gradual Escalation Protocols: Titrating from half doses in Week 1 to full doses in Week 2 prevented acute shock to patient neurological systems.
- Objective Verification Metrics: Utilizing validated scoring models like the CMAI alongside clinician-rated global improvement metrics prevented subjective bias from distorting safety outcomes.
- First-Line Policy Enforcement: As noted by Dr. Elizabeth Edgerly of the Alzheimer's Association, cannabinoid therapeutics do not replace nonpharmacological first-line strategies—such as environmental modifications and structured routines—but serve as an audited tier when standard care fails.
Closing the gap in clinical knowledge is an ongoing challenge across healthcare. As documented in our study of brain health knowledge gaps in older adults, clear guidelines and empirical evidence are essential for informed decision-making.
Addressing Terminal Dementia and End-of-Life Palliative Needs
Agitation affects roughly 50% of advanced dementia patients near the end of life. More than one-third of these individuals remain severely symptomatic even when prescribed aggressive off-label cocktails.
Because late-stage cognitive decline strips away verbal expression, distress manifests as physical tension: moaning, repetitive vocalizations, continuous calling out, verbal hostility, and physical acts like hitting, scratching, or throwing objects. For families and care facility staff, managing these behaviors without heavy sedation has felt impossible.
The LiBBY study—which also completed a 12-week open-label extension co-funded by the Alzheimer's Association—proves that rigorous, double-blind trials can be executed safely in terminal care settings. By substituting toxic off-label sedative habits with standardized, ratio-controlled THC/CBD formulations, clinicians finally have a path toward quiet comfort and genuine dignity for end-of-life patients.
